Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Healthy Male Adults Healthy, male subjects aged 18 to 35 years inclusive Subjects must be in good general health, as determined by the investigator Subject's pre-study physical examination, vital signs and electrocardiogram (ECG) are normal or do not show any clinically significant abnormalities as determined by the investigator. Vital signs must not have any clinically significant deviations outside of the following ranges when measured sitting after 5 minutes rest: 1. Heart rate: 40 to 90 beats per minute 2. Systolic blood pressure (BP): 90 to 140 mmHg 3. Diastolic BP: 50 to 90 mmHg 4. Oral temperature: 36.0 to 37.5°C 5. Respiratory rate: 12 breaths per minute Body Mass Index (BMI) of 18.5 9 kg/m2 (both inclusive) Subjects must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent Provision of written informed consent  An ear, nose and throat (ENT) specialist will inspect the noses of all individuals who enter the study. In order to participate in the study subjects must not meet any of the following criteria Individuals showing major septal deviation or a significantly altered nasal epithelium Participants with evidence of previous nasal disease, surgery, and dependence on inhaled drugs Individuals with current significant nasal congestion due to common colds Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or metabolic disorder Subjects with current or history of, any clinically significant disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs Subject is taking any regular prescribed or over-the-counter (OTC) medications including vitamin supplements and herbal remedies. There must be at least 14 days between stopping these products and the first dose of study medication) Systemic illness requiring treatment within 2 weeks prior to Study Day 1 History of significant drug or alcohol abuse (as per a self-report measure / instrument; World Health Organisation criteria/Alcohol use disorders identification test/Drug use disorders identification test). Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study Self-reported significant psychiatric conditions